AMAZENTIS
17.5.2022 17:06:07 CEST | Business Wire | Press release
Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed clinical and translational journal Cell Reports Medicine published new clinical results showing the muscle health benefits of the gut microbiome postbiotic Urolithin A. Age-associated muscle decline can start as early as 40 years old and there are currently no effective interventions to counteract it other than exercise.
This milestone study showed that daily intake of Amazentis’ proprietary Urolithin A, Mitopure, significantly improved muscle strength by 12% after four months. These findings further validate Mitopure’s benefits for muscle and mitochondrial health and show it is safe and well tolerated. Mitopure works by supporting the cells’ ability to renew their powerplants, the mitochondria, during the aging process. Muscles have a high demand for energy and there are a very large number of mitochondria in muscle cells.
Previous research showed that Mitopure improved muscle endurance, reduced inflammation, and resulted in healthier mitochondrial function in older adults 65 to 90 years old. This new double-blind, placebo-controlled trial in middle-aged adults 40 to 64 years old (n=88) was conducted in London, Ontario, Canada following approvals from Health Canada and an independent IRB. Participants were randomized to receive daily supplementation with either 500mg, 1,000mg Mitopure or placebo for 4 months. Muscle strength, exercise performance tests and biomarkers of healthy mitochondrial function and inflammation in skeletal muscle biopsies and blood plasma were assessed at baseline, 2 months and 4 months.
- Two measures of skeletal muscle strength were improved in the supplemented groups compared to the placebo group. Muscle strength in the hamstring skeletal muscle was significantly increased in both 500mg (+12%) and 1,000mg groups (+9.8%). Muscle strength during knee flexion was also significantly improved at both 500mg (+10.6%) and 1,000mg doses (+10.5%)
- Clinically meaningful improvements on aerobic endurance (+ 10% in peak oxygen consumption [VO2]), physical performance (+ 33 meters on the 6 min walk test), and power output (+5%) were observed in the 1,000mg group, though not statistically significant
- The blood tests and biopsies showed a significant improvement in biomarkers of healthy mitochondrial function and reduced inflammation
“These results are exciting because this is the first in human demonstration that Urolithin A repairs the mitochondria via mitophagy and can translate to meaningful physiological benefits. Furthermore, the improvement in strength and exercise-performance occurred in the absence of any changes to participants exercise routine,” explained Johan Auwerx, MD, PhD, co-author and Professor at the Swiss Federal Institute of Technology EPFL.
This is an important discovery in longevity and muscle health research. Aging is associated with a decline in mitochondrial function which can lead to reduced exercise capacity, muscle endurance and strength. Urolithin A is the first and only compound that has been clinically shown to improve muscle function by renewing the mitochondria through a potent biological quality control mechanism called mitophagy. By activating this important biological pathway, Mitopure promotes healthy aging and improved muscle health and performance.
“This study further validates the role of mitochondrial health as an important pillar of vitality and shows Mitopure is a first in class nutrient that meaningfully impacts muscle health. We are proud to offer this proprietary form of Urolithin A in our Timeline® brand and inside Nestlé Health Science products,” said Chris Rinsch, CEO and Co-Founder of Amazentis. “We remain committed to pioneering clinically validated products that optimize cellular health with the mission of keeping millions of people healthier for longer”.
In addition, Amazentis also announced that Dr. Eric Verdin has joined the Amazentis scientific advisory board. Dr. Verdin is the president and chief executive officer of the Buck Institute for Research on Aging and he has dedicated his career to studying longevity with the goal of transforming everyone into healthy centenarians.
“Mitochondrial decline is a key hallmark of aging and poor metabolic health. This study is an important milestone and shows that Urolithin A could be a gamechanger in our field.” said. Dr. Eric Verdin.
Doi: 10.1016/j.xcrm.2022.100633
About Amazentis
Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure™ Urolithin A in top peer reviewed scientific journals including Nature Medicine
(doi:10.1038/nm.4132), Nature Metabolism
(doi: 10.1038/s42255-019-0073-4), JAMA Network Open
(doi:10.1001/jamanetworkopen.2021.44279) and European Journal of Clinical Nutrition
(https://doi.org/10.1038/s41430-021-00950-1
). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™ linked to mitochondrial and cellular health. For more information on Amazentis, please visit www.amazentis.com
.
About Mitopure™
Mitopure™ is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure™ has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure™ has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure™ has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit www.mitopure.com
.
About Timeline®
Timeline® Nutrition is brought to you by the inventors of Mitopure™. This novel, science-first brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of clinically validated nutritional products to optimize cellular health. For more information, please visit www.timelinenutrition.com
.
Related Links
https://www.timelinenutrition.com
https://www.amazentis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005659/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wise Selects Navan to Modernize Global Travel Program10.11.2026 10:00:00 CET | Press release
Global financial technology company plans to improve traveler choice, cost control and visibility Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Wise (Nasdaq:WSE, LSE:WISE), the global financial technology company building the best way to move and manage the world's money, has selected Navan to manage its business travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109603155/en/ Global financial technology company plans to improve traveler choice, cost control and visibility “Our teams travel across the world to work together and support our customers, so it's important that booking and managing travel is straightforward,” said Hanro Hennig, VP Global Real Estate, Workplace and Risk at Wise. “We're working with Navan to make that experience simpler, while giving us better visibility and control over travel costs.” Key anticipated benefits of the partnershi
Quectel Launches EG216Q-GL and BG950Q-GL to Give IoT Device Makers a More Cost-efficient, Lower-power Upgrade Path10.11.2026 10:00:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announced the EG216Q-GL and BG950Q-GL, two next-generation global cellular IoT modules based on Qualcomm technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110650568/en/ Quectel launches EG216Q-GL and BG950Q-GL to give IoT device makers a more cost-efficient, lower-power upgrade path Built in Quectel’s widely adopted EG2 and BG95 form factors, the modules give device makers a direct route from established legacy platforms to a more cost- and power-optimized generation. Customers can reuse the board designs and development work they already have. The EG216Q-GL is an LTE Cat 1bis module for customers whose designs use Quectel’s EG2-footprint modules. These include the EC2x series, EC200A series, EG25-G, EG25-GL, EG21-G and EG21-GL, as well as the UC200A-GL. Because it shares their form factor, manufacturers can upgrade while keeping their
Heitman Partners with Talliosake to Establish Nordic Drive-Up Self-Storage Platform Talli10.11.2026 10:00:00 CET | Press release
Since 1996, Heitman has invested over $15 billion in 1,600 self-storage properties across 14 countries Heitman LLC (“Heitman”), a global real estate investment management firm, today announced the launch of Talli, a new Nordic drive-up self-storage platform established through the acquisition of the majority of Talliosake Oy’s (“Talliosake”) rental operating business. Talliosake will remain a minority investor in Talli. Completed on behalf of Heitman’s European value strategy, the transaction establishes a platform for expansion across Finland and Sweden and builds on Heitman’s Nordic self-storage presence following its acquisition of the Servistore platform in Sweden in 2024. The Talli platform brings together the experienced management team that has driven Talliosake’s growth with Heitman’s global investment and operational capabilities. Since 2010, Talliosake has delivered more than 6,400 drive-up self-storage units across 230 properties in Finland and Sweden, building deep expertis
OBI Group Will Adopt Blue Yonder Solutions to Unify Demand Planning and Replenishment Across 660+ European Stores10.11.2026 09:00:00 CET | Press release
Germany-based Home and Garden retailer replaces multiple systems with a single AI-driven planning platform spanning 10 countries OBI Group, a leading European Home and Garden retailer, has begun adopting Blue Yonder Demand Planning and end-to-end replenishment capabilities across its stores and distribution centers, with plans to ultimately deploy them to more than 660 stores across all of its markets. The deployment replaces multiple systems with a single, scalable platform. It also gives OBI AI-enabled forecasting and automated replenishment from distribution centers to store shelves, improving product availability for millions of customers across Europe. OBI selected Blue Yonder to consolidate fragmented planning systems into one integrated platform. That helps improve forecast accuracy across assortment types and planning timeframes while standardizing forecasting and replenishment processes across its network. Blue Yonder’s machine-learning capabilities and the prospect of future
Light Frame Raises $5.1 Million to Modernise Private Banking Technology10.11.2026 07:00:00 CET | Press release
The oversubscribed Seed round, led by Fortino Ventures, follows growing institutional adoption of Light Frame's next-generation core banking and portfolio management platform across EMEA. Light Frame, the financial technology company providing modern core banking and portfolio management software for the wealth industry, today announced the successful closing of an oversubscribed $5.1 million Seed financing round. The round was led by Fortino Ventures, with participation from Sidekick Partners, Tenity, Chamaeleon, and Altair Capital, alongside existing investors including Rogue Venture Partners, New Stack Ventures, and Studio Alpha. The financing comes amid growing institutional adoption of Light Frame's technology across EMEA, where the company is supporting live client operations and expanding its presence in the private banking and wealth management markets. Revolutionizing the wealth industry Across the wealth industry, institutions continue to rely on technology built on architect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
